A Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Anti-Tumor Activity of ABBV321 in Subjects with Advanced Solid Tumors Associated with Overexpression of the Epidermal Growth Factor Receptor (EGFR)

Project: Research

Project Details

Project Description

NMA HREC Reference Number: HREC/17/Austin/305
NMA SSA Reference Number: SSA/36126/MonH-2020-207426(v1)
Monash Health Reference: RES-20-0000-214X
Effective start/end date21/07/2020/07/25


  • clinical trial
  • phase 1 study
  • treatment efficacy
  • treatment safety
  • solid tumours
  • Pharmacokinetics